Researchers have identified how the MYC protein helps pancreatic cancer evade immune detection, while a separate team discovered methods to permanently switch off cancer genes in leukemia through epigenetic therapy targeting Menin and DOT1L proteins.
Scientists at UC San Diego have identified N4BP2 as the enzyme responsible for chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers that enables rapid tumor evolution and treatment resistance.
Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07440290 |
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07432932 |
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients |
RECRUITING | |
| NCT07391215 |
5G-PEARL: Paxalisib in Malignant Brain Tumours |
RECRUITING | PHASE1/PHASE2 |
| NCT07279454 |
The EAT-FIBRE Study. |
NOT_YET_RECRUITING | NA |
| NCT07209774 |
Healthspan Connect Programme of Research |
NOT_YET_RECRUITING | |
| NCT07172958 |
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) |
RECRUITING | PHASE1 |
| NCT07095517 |
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors |
RECRUITING | PHASE1 |
| NCT06988475 |
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations |
RECRUITING | PHASE2/PHASE3 |
| NCT06632236 |
5G-EMERALD: Amivantamab in Malignant Brain Tumours |
RECRUITING | PHASE1 |
| NCT06630260 |
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours |
RECRUITING | PHASE1/PHASE2 |
